-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] In recent years, the nervous system drug market has been affected by many aspects and is ushering in further grow.
For example, the sales revenue of central nervous system drugs in China has increased from 144 billion yuan in 2015 to 203 billion yuan in 2019, with a compound annual growth rate of about
It is estimated that by 2024, this drug market is expected to reach 259 billion yuan Yu.
The industry said that with the launch of new actions by various companies, the field of neurological drugs will usher in a new situati.
It is understood that two hot research directions in the field of neurotherapy: Alzheimer's disease (AD) and Parkinson's disease (PD), have actually begun to welcome a large number of pharmaceutical companies to compete for the tra.
The AD market continues to be hot, and a large number of companies are accelerating their deployment in Alzheimer's disease (A.
According to the "World Alzheimer's Disease Report 2018", there is a dementia patient about every 3 seconds in the world, and there are at least one dementia patient in the wor.
There are 50 million dementia patients, and it is expected that this number will reach 150 million in 2050; among them, about 60%-70% are AD patien.
At present, Eli Lilly is one of the companies that has invested a lot in Alzheimer's disease (A.
Eli Lilly's main R&D spending in 2021 is related to two research projects, one of which is the Alzheimer's disease treatment drug donanem.
Donanemab is a monoclonal antibody targeting N3pG for the treatment of early Alzheimer's disea.
It has been granted breakthrough therapy designation (BTD) by the US F.
At present, the company has submitted a rolling biologics license application (BLA) to the FDA to seek Accelerated approval of the dr.
In 2021, Roche will also focus on increasing its research and development investment in neuroscience, including the RG1450 project for Alzheimer's disease (A.
RG1450 stands for "Gantenerumab", a fully humanized IgG1 monoclonal antibody for subcutaneous injection that binds and neutralizes AD-associated β-amyloid aggregation, which occurs when β-amyloid forms plaques in the brain The accumulation interferes with the normal function of brain cel.
Currently, Roche is conducting a phase III clinical trial of Gantenerum.
In China, anti-AD drugs have also become a hot track for pharmaceutical companies' research and developme.
At present, some domestic pharmaceutical companies, including Green Valley Pharmaceuticals, Sunshine Pharmaceuticals, Hisun Pharmaceuticals, Tonghua Jinma, e.
, are accelerating the research and development of new and generic drugs for Alzheimer's disea.
Among them, it is worth mentioning that in November 2019, GV-971 (Sodium Mannat Capsule, trade name "Nine Phase One") developed by Ocean University of China, Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Shanghai Green Valley was approved for conditional listi.
, has become China's original and first new drug for the treatment of Alzheimer's disease targeting the brain-gut axis for the treatment of Alzheimer's disease or Alzheimer's disea.
In addition, in order to further alleviate the burden of Alzheimer's disease patients in China, pharmaceutical companies are accelerating the development of new drugs and providing patients with more choic.
At the same time, the country is also accelerating the entry of AD drugs into medical insuran.
On December 3, 2021, the National Medical Insurance Administration announced the adjustment results of the National Medical Insurance Drug List in 202 A total of 74 drugs have been added to the li.
in .
More than 50 drugs have been approved in the PD market Parkinson's disease (PD) is the second largest neurodegenerative disease in the world, second only to Alzheimer's disea.
According to 2018 statistics, more than 10 million people around the world suffer from PD, and the number is still risi.
In recent years, based on the huge patient population and treatment needs, many pharmaceutical companies have begun to deploy in this fie.
For example, in 2021, Novartis will invest US$5 billion to cooperate with Belgian pharmaceutical company UCB (UCB) to jointly develop two anti-Parkinson's disease (PD) drugs UCB0599 and UCB785Among them, UCB0599 is a small molecule α-nuclein misfolding inhibitor, which is currently in the phase II clinical tri.
The latter has developed and commercialized rights to apomorphine subcutaneous injection for the treatment of PD in mainland China, Hong Kong and Mac.
At present, with the efforts of many pharmaceutical companies, more than 50 PD drugs have been approved for marketing in the wor.
According to the different mechanisms of action, the marketed PD drugs can be roughly divided into anticholinergic drugs, dopamine release drugs, dopamine replacement drugs, dopamine receptor agonists, B-type monoamine oxidase inhibitors, catechol-O-methyl There are six classes of transferase (COMT) inhibito.
Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute an investment recommendation for anyone
For example, the sales revenue of central nervous system drugs in China has increased from 144 billion yuan in 2015 to 203 billion yuan in 2019, with a compound annual growth rate of about
It is estimated that by 2024, this drug market is expected to reach 259 billion yuan Yu.
The industry said that with the launch of new actions by various companies, the field of neurological drugs will usher in a new situati.
It is understood that two hot research directions in the field of neurotherapy: Alzheimer's disease (AD) and Parkinson's disease (PD), have actually begun to welcome a large number of pharmaceutical companies to compete for the tra.
The AD market continues to be hot, and a large number of companies are accelerating their deployment in Alzheimer's disease (A.
According to the "World Alzheimer's Disease Report 2018", there is a dementia patient about every 3 seconds in the world, and there are at least one dementia patient in the wor.
There are 50 million dementia patients, and it is expected that this number will reach 150 million in 2050; among them, about 60%-70% are AD patien.
At present, Eli Lilly is one of the companies that has invested a lot in Alzheimer's disease (A.
Eli Lilly's main R&D spending in 2021 is related to two research projects, one of which is the Alzheimer's disease treatment drug donanem.
Donanemab is a monoclonal antibody targeting N3pG for the treatment of early Alzheimer's disea.
It has been granted breakthrough therapy designation (BTD) by the US F.
At present, the company has submitted a rolling biologics license application (BLA) to the FDA to seek Accelerated approval of the dr.
In 2021, Roche will also focus on increasing its research and development investment in neuroscience, including the RG1450 project for Alzheimer's disease (A.
RG1450 stands for "Gantenerumab", a fully humanized IgG1 monoclonal antibody for subcutaneous injection that binds and neutralizes AD-associated β-amyloid aggregation, which occurs when β-amyloid forms plaques in the brain The accumulation interferes with the normal function of brain cel.
Currently, Roche is conducting a phase III clinical trial of Gantenerum.
In China, anti-AD drugs have also become a hot track for pharmaceutical companies' research and developme.
At present, some domestic pharmaceutical companies, including Green Valley Pharmaceuticals, Sunshine Pharmaceuticals, Hisun Pharmaceuticals, Tonghua Jinma, e.
, are accelerating the research and development of new and generic drugs for Alzheimer's disea.
Among them, it is worth mentioning that in November 2019, GV-971 (Sodium Mannat Capsule, trade name "Nine Phase One") developed by Ocean University of China, Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Shanghai Green Valley was approved for conditional listi.
, has become China's original and first new drug for the treatment of Alzheimer's disease targeting the brain-gut axis for the treatment of Alzheimer's disease or Alzheimer's disea.
In addition, in order to further alleviate the burden of Alzheimer's disease patients in China, pharmaceutical companies are accelerating the development of new drugs and providing patients with more choic.
At the same time, the country is also accelerating the entry of AD drugs into medical insuran.
On December 3, 2021, the National Medical Insurance Administration announced the adjustment results of the National Medical Insurance Drug List in 202 A total of 74 drugs have been added to the li.
in .
More than 50 drugs have been approved in the PD market Parkinson's disease (PD) is the second largest neurodegenerative disease in the world, second only to Alzheimer's disea.
According to 2018 statistics, more than 10 million people around the world suffer from PD, and the number is still risi.
In recent years, based on the huge patient population and treatment needs, many pharmaceutical companies have begun to deploy in this fie.
For example, in 2021, Novartis will invest US$5 billion to cooperate with Belgian pharmaceutical company UCB (UCB) to jointly develop two anti-Parkinson's disease (PD) drugs UCB0599 and UCB785Among them, UCB0599 is a small molecule α-nuclein misfolding inhibitor, which is currently in the phase II clinical tri.
The latter has developed and commercialized rights to apomorphine subcutaneous injection for the treatment of PD in mainland China, Hong Kong and Mac.
At present, with the efforts of many pharmaceutical companies, more than 50 PD drugs have been approved for marketing in the wor.
According to the different mechanisms of action, the marketed PD drugs can be roughly divided into anticholinergic drugs, dopamine release drugs, dopamine replacement drugs, dopamine receptor agonists, B-type monoamine oxidase inhibitors, catechol-O-methyl There are six classes of transferase (COMT) inhibito.
Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute an investment recommendation for anyone
